Use of total bryostatin for preparing medicine for anti SARS coronavirus

A technology of coronavirus, bryozoa, applied in the field of medicine

Inactive Publication Date: 2004-11-17
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But do not see the report about preparing anti-atypical pneumonia SARS coronavirus drug with total bryozolide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] The initial concentration of total bryozolide was 500 μg / ml, and the 5-fold dilution was 100 μg / ml, 20 μg / ml and 4 μg / ml. Test according to the above test method, and carry out the calculation and evaluation of the anti-SARS virus activity of total bryozolides with reference to the control sample. The test results are shown in Table 1.

[0013] Table 1 Anti-SARS effect of total bryozolides

[0014] Concentration (μg / ml) CPE Cell Protection Rate

[0015] 100++2.37

[0016] 20++2.85

[0017] 4 +++ 2.10

[0018] Cytopathic pathology method (CPE): "-" means that the cell attachment is complete, no obvious detachment, but the number of cells is not compared; "+" means the degree of cytopathic changes, 75% are "++++". Infected cell protection rate: By comparing the OD values ​​of the virus control, cell control and sample control groups, the protective activity of the sample on virus-infected cells was calculated. If t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention refers to a field of medicine technique, concretely, making the anti-SARS virus active screening on the marine bryozoan bugula neritina total lactone, and at the concentration above 4 micron g / ml, showing the activities of resisting SARS virus and protecting infected cells. It provides a scientific basis for the research and development of new anti-SARS virus medicines and has an important significance for developing and using the sea medicine resources in our country.

Description

technical field [0001] The invention relates to the technical field of medicine, and refers to the new use of total bryozolides for preparing anti-atypical pneumonia SARS coronavirus drugs. Background technique [0002] The total bryozoa Bugula neritina is a marine benthic animal. In 1982, Professor Pettit of the University of Arizona isolated the first macrolide compound with anticancer activity - bryostatin 1. Since then, American and Japanese scholars have obtained 17 such components from the total bryozoa produced in different sea areas. Among them, bryostatin 1 was approved by the FDA to enter Phase Π clinical trial in the United States. In addition, studies of such drugs are also being carried out in Europe and Japan. Clinical trials are mainly used for the treatment of leukemia, lymphoma, kidney cancer, cervical cancer, melanoma and other cancers. The first patient with melanoma after treatment is still living a healthy life after 5 years. Three patients with uteri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61K31/7048A61P11/00A61P31/14
Inventor 易杨华林厚文姚新生李玲孙鹏刘宝姝
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap